Table 6.

Factors Affecting Poor Outcomes* According to Type of TNF-α Inhibitor Treatment in Patients with Ulcerative Colitis

Variable	Univariate analysis		Multivariate analysis
	p-value		p-value	Adjusted HR† (95% CI)
Infliximab subgroup (n=83)
Age (>40/≤40 yr)	0.952
Sex (male/female)	0.144
CRP (>5/≤5 mg/L)	0.004		0.002	2.41 (1.36–4.26)
Disease extent (extensive/left-sided)	0.789
Adalimumab subgroup (n=30)
Age (>40/≤40 yr)	0.504
Sex (male/female)	0.309
CRP (>5/≤5 mg/L)	0.167		0.071	3.39 (0.90–12.77)
Disease extent (extensive/left-sided)	0.323

TNF, tumor necrosis factor; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein.

*Poor outcomes are defined as the sum of the following events: all-cause hospitalization, ulcerative colitis-related hospitalization, corticosteroid prescription, discontinuation of TNF-α inhibitors, and switching to a secondary TNF-α inhibitor; †A HR of >1 indicates a benefit of infliximab compared with adalimumab.